Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 for Oral Mucositis in Head and Neck Cancer
NCT06532279Phase 2Recruiting
- Sponsor
- NRG Oncology
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of manganese butoxyethyl pyridyl porphyrin in oral mucositis (OM), sponsored by NRG Oncology. Started Jun 2025; status: recruiting.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT06532279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532279.